Effects of β-funaltrexamine on radiolabeled opioid binding Journal Article


Authors: Recht, L. D.; Pasternak, G. W.
Article Title: Effects of β-funaltrexamine on radiolabeled opioid binding
Abstract: β-Funaltrexamine (β-FNA) potently competed with the binding of a series of radiolabeled opiates and opioid peptides in standard binding assays with IC50 values under 10 nM. In addition, higher concentrations of β-FNA produced an irreversible inhibition of binding which was relatively selective for μ receptors: δ binding was not affected much. The production of irreversible inhibition of [3H]dihydromorphine binding required concentrations of β-FNA over 10-fold higher than β-FNA concentrations needed in standard competition studies. Both μ1 and μ2 sites were irreversibly inhibited by β-FNA, but μ1 sites were more sensitive. The reversible and irreversible inhibition in these in vitro binding assays by β-FNA were quite similar to naloxonazine. However, the activity of β-FNA in the guinea-pig ileum suggests that it may not distinguish between μ1 and gm2 receptors as effectively as naloxonazine in bioassays and in vivo. © 1987.
Keywords: nonhuman; animal cell; animal; central nervous system; drug receptor binding; drug antagonism; brain; rat; rats; radioisotope; morphine; receptors, opioid, mu; drug binding; pharmacokinetics; in vitro; naloxone; opiate receptor; beta funaltrexamine; naltrexone; binding, competitive; naloxonazine; opiate derivative; opiate receptors; rats, inbred strains; narcotic antagonists; receptors, opioid; β-funaltrexamine; male; priority journal; dihydromorphine; enkephalin, leucine-2-alanine; support, u.s. gov't, p.h.s.; enkephalin, leucine; μ1-receptors
Journal Title: European Journal of Pharmacology
Volume: 140
Issue: 2
ISSN: 0014-2999
Publisher: Elsevier B.V.  
Date Published: 1987-08-11
Start Page: 209
End Page: 214
Language: English
DOI: 10.1016/0014-2999(87)90807-7
PUBMED: 2822439
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gavril W Pasternak
    414 Pasternak